Improving Cardiac Secondary Prevention

Improving Cardiac Secondary Prevention Through Personalized Biomarker Knowledge

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03269708

Enrollment

200

Registered

2017-09-01

Start date

2019-03-01

Completion date

2024-09-30

Last updated

2024-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Secondary Prevention

Brief summary

The purpose of this study is to determine whether providing individuals with personalized information on cellular aging, including telomere length, will stimulate them to adhere to cardiac prevention strategies and improve exercise capacity.

Detailed description

Individuals who have sustained a heart attack are at considerable risk for future cardiac events. A cardiac rehabilitation and exercise program can reduce this risk but it remains a challenge to adopt optimum lifestyle changes. We will determine whether providing individuals with information on leukocyte telomere length, will motivate them to improve their exercise performance. We will test whether professionally conveying this information will stimulate an individual to adhere to proven cardiac prevention strategies, looking at the extent to which one's exercise capacity improves over time.

Interventions

BEHAVIORALEducation regarding telomere length

Teaching concepts of cellular aging and telomere length

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1\. Individuals who have sustained a myocardial infarction and entered the cardiac rehabilitation program

Exclusion criteria

1. Individuals with genetic mutations that affect telomere length 2. Individuals who may not have the mental capacity to understanding the ramifications of risk biomarkers

Design outcomes

Primary

Measure	Time frame	Description
Exercise capacity based on cardiopulmonary exercise testing	after 6-month cardiac rehabilitation program	Online VO2 maximum

Secondary

Measure	Time frame	Description
Adherence to supervised exercise sessions	6 months	Proportion of prescribed supervised on-site exercise sessions attended
Activity assessment	6 months	Garmin recording

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026